Lung squamous cell carcinoma with hemoptysis after vaccination with tozinameran (BNT162b2, Pfizer‐BioNTech)
Abstract A 66‐year‐old man with squamous cell carcinoma had been receiving chemoradiation therapy after stereotactic radiotherapy for brain metastases. Atezolizumab was initiated as second‐line therapy, after which the patient became progression‐ and recurrence‐free. Four days after his second dose...
Guardado en:
Autores principales: | Toshiyuki Sumi, Yuta Nagahisa, Keigo Matsuura, Motoki Sekikawa, Yuichi Yamada, Hisashi Nakata, Hirofumi Chiba |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wiley
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b19949a1ae4845508d85bac3487a9988 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Neutrophilic urticarial dermatosis following BNT162b2 (Pfizer–BioNTech) COVID‐19 vaccination
por: Akihiro Matsubara, et al.
Publicado: (2021) -
Stability testing of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine: a translational study in UK vaccination centres
por: Michael Cross, et al.
Publicado: (2021) -
Efficacy of Pfizer-BioNTech in SARS-CoV-2 Delta cluster
por: Hannah E. Landsberg, MSN, MPH, et al.
Publicado: (2022) -
Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers
por: Rami Alqassieh, et al.
Publicado: (2021) -
Removal of hematoma due to massive hemoptysis after transbronchial biopsy: a case report
por: Harushi Ueno, et al.
Publicado: (2021)